TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/26/2025
Back to search
Official data from USPTO
N NETRIS PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
17
Latest update
10/14/2025
Trademark type
Combined
Nice classes
42
Filing date
10/21/2022
Registration date
11/28/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/28/2023
Last transaction
10/14/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
Lyon, FR
Examiner
MCCRARY,LISA J
Law office
T80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "NETRIS Pharma" written in a stylized font, where the word "NETRIS" is in black bold style, while the word "Pharma" is blue. The wording is preceded by a blue square with round corners with a white circle in the middle over which is the stylized blue letter "N". The white outside the logo is just transparent background and is not claimed as a feature of the mark.
Holders and representatives
Holders
N. P. (pessoa física)
Representatives
Paul Cosmovici
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Medical and pharmaceutical research services; Scientific research for medical purposes in the field of cancerous diseases; Medical research in the field of oncology; Scientific research for medical purposes in the area of cancerous diseases; Biological research; Clinical research in the field of treatment of cancerous diseases; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Development of pharmaceutical preparations and medicines; Medical laboratory services; Providing scientific information in the field of medical disorders and their treatment; Research on the subject of pharmaceuticals; Conducting clinical trials for others relating to pharmaceutical products in the field of cancerous diseases; Pharmaceutical products development; Consultancy relating to pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Information on the subject of scientific research in the field of biochemistry and biotechnology; Research relating to biotechnology; Research and development in the field of biotechnology; Research and development in the field of microorganisms and cells
Publications
History of USPTO decisions and trademark events.
17 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/26/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/26/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/28/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
11/28/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/12/2023
PUBO
PUBLISHED FOR OPPOSITION
09/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/23/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/10/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
08/10/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/10/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
08/10/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/10/2023
DOCK
ASSIGNED TO EXAMINER
08/06/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/06/2022
NWAP
NEW APPLICATION ENTERED
10/25/2022
Continuous trademark protection
Get notified about every new filing that threatens N NETRIS PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.